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a  b  s  t  r  a  c  t
This study  investigated  the  effects  of  Na2SO3 on  the  fat metabolism  in  human  normal  diploid  HL-
7702  (referred  as  L-02)  hepatocytes.  After  24  h and  48 h,  treatment  with  different  concentrations  of
Na2SO3, the  intra and  extra-hepatocellular  triglyceride  (TG)  contents  of  L-02  were  determined  using
chemical-enzymatic  method.  The  contents  of  very  low-density  lipoprotein  (VLDL)  and apolipoprotein
B100  (apoB100)  in  the  culture  supernatants  were  determined  using  enzyme-linked  immunosorbent
assay  (ELISA).  Western  blot  was applied  to detect  the  expressions  of  fatty  acid  oxidation  and  fat  synthesis
related  proteins,  VLDL  assembly  and  secretion  in  L-02  cells.
Results:  Na2SO3 treatment  (10  mM,  24 h/48  h) signiﬁcantly  increased  the  intra  TG  level in the  hepatocytes.
Different  concentrations  of Na2SO3 increased  the  extra-hepatocellular  TG content.  After 24  h  exposure,
the  extracellular  VLDL  levels  and  secretions  of apoB100  in  0.1–10  mM  Na2SO3 groups  were  signiﬁcantlyatty acid oxidation
at synthesis
LDL uptake
higher  than  that  of  the  negative  control  (P <  0.05).  Meanwhile,  the  expression  of  CPT1  and  SREBP1  protein
were  signiﬁcantly  reduced  by Na2SO3. MTP  and TGH  protein  expressions  were  signiﬁcantly  elevated  in
each  Na2SO3 treatment  group.  The  expression  level  of LDLR  in hepatocytes  was reduced  by  Na2SO3.
Conclusion:  Na2SO3 exposure  may  promote  the  hepatocellular  VLDL  assembly  and  secretion,  through
increasing  of MTP  and  TGH  expressions  and  inhibiting  the  uptake  of  extracelluar  VLDL.
©  2015  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the CC. Introduction
Na2SO3 is the main residue in traditional food and pharmaceuti-
al products after sulfur fumigation. It is widely used as an additive
n various dried fruits (such as pistachio nuts, preserved fruit, etc.),
harmaceutical products and alcoholic drinks [1,2]. Sulfur dioxide
an be transformed to Na2SO3 after inhalation via respiratory tract;
ventually this compound enters other organs including the liver
nd kidney via the blood circulation [3].
However, extensive studies have reported that Na2SO3 is able
o damage the respiratory, cardiovascular and nervous systems
4–6]. For example, respiratory system diseases caused by Na2SO3
ncluding asthma [8–10], chronic mucous hypersecretion, cough,
hintis, bronchitis [11,12] and even lung cancer [7]. Na2SO3 expo-
Abbreviation: TG, triglyceride; VLDL, very low-density lipoprotein; apoB100,
polipoprotein B100; ELISA, enzyme-linked immunosorbent assay; CPT1, carni-
ine palmitoyl transferase 1; SREBP1, sterol regulatory element binding protein-1;
TP, microsomal triglyceride transfer protein; TGH, triglyceride hydrolase; Arf1,
DP-ribosylation factor-1; COP I, coated protein I; LDLR, low-density lipoprotein
eceptor; NAFLD, Nonalcoholic fatty liver disease.
∗ Corresponding author.
E-mail address: jybai66@aliyun.com (J. Bai).
ttp://dx.doi.org/10.1016/j.toxrep.2015.12.005
214-7500/© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access
c-nd/4.0/).BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
sure can also increase the mortality of cardiovascular disease [13]
and the risk of acute stroke [14]. Na2SO3 can impair nervous system
by causing synaptic injury, spatial learning and memory impair-
ment and an increase in reactive oxygen species and a decrease in
ATP in Neuro-2a and PC12 cells [5,6,15]. However, It is reported
that deﬁciency of sulphite oxidase could lead to mental retarda-
tion, neurological symptoms such as spastic quadriplegia, and early
death [16,17]. In particular, Na2SO3 is more dangerous to sensi-
tive individuals, Vally et al. reported that topical, oral or parenteral
Na2SO3 exposure induces a range of adverse clinical effects, ranging
from dermatitis, urticaria, ﬂushing, hypotension, abdominal pain
and diarrhoea to life-threatening anaphylactic and asthmatic reac-
tions in sensitive individuals [18].
Although different organs have different reactivities to Na2SO3,
but they also share some similar mechanisms to Na2SO3 injury.
For example, Na2SO3 exposure can change the redox state in liver,
kidney and nervous system [19–21]. Some studies have reported
that mice might become hyperlipidemic after exposure to sul-
fur dioxide, and triglyceride (TG) content in hepatocytes was
increased [22,23], Bai and Meng. suggested that Na2SO3 may  cause
metabolic disorders in mice hepatocytes.The molecular mecha-
nism of Na2SO3 inﬂuence on fat metabolic disorders in human
liver remains unclear. Because both extrahepatic and intrahepatic
 article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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Table  1
Primary antibodies used in western blot.
Primary antibody Company Catalogue # Dilution
Rabbit anti-human
MTP
Abcam Ab63467 1:1000
Rabbit anti-human
LDLR
Abcam Ab52818 1:1000
Rabbit anti-human
COP 
Abcam Ab2899 1:1000
Rabbit anti-human
TGH
Abcam Ab68190 1:3000
Rabbit anti-human
Arf1
Epitomics #1635-1 1:2000
Rabbit anti-human
CPT1a
Protein Tech, China 15184-1-AP 1:1000
Rabbit anti-human
SREBP1c
Protein Tech, China 14088-1-AP 1:1000
Mouse anti-human
-actin
Wuhan Boster Biological
Technology Co., Ltd., China
BM0005 1:1000
Table 2
Secondary antibodies used in western blot.
Secondary antibody Company Catalogue # Dilution
Goat anti-rabbit IgG Wuhan Boster Biological
Technology Co., Ltd., China
BA1050 1:4000
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cGoat anti-mouse IgG Wuhan Boster Biological
Technology Co., Ltd., China
BA1055 1:4000
actors cause fat metabolic disorders [28], Nonalcoholic fatty liver
isease (NAFLD) is now threatening growing number of people both
n developed and developing countries [24,26,27]. Our study targets
n the intrahepatic factors include abnormalities in fat synthesis
nd fatty acid decomposition of the hepatocytes, as well as abnor-
al  assembly and secretion of very low-density lipoprotein (VLDL)
29]. The most studied fat synthesis regulation protein is sterol
egulatory element binding protein-1(SREBP1), which chieﬂy reg-
lates the synthesis of fatty acids [30] and the key enzyme of fatty
cid decomposition is carnitine palmitoyl transferase 1(CPT1b)
n liver [31]. The VLDL assembly and secretion related proteins
ncludes MTP, TGH, Arf1 and COP I, etc. [32,34–36]. In the present
tudy, in vitro experiments were used to investigate the changes
f above intrahepatic factors associated with fat metabolism after
reating L-02 hepatocytes with different concentrations of Na2SO3.
. Materials and methods
.1. Materials
The normal human diploid hepatocytes (HL-7702; referred as
-02) were purchased from Shanghai Institute of Cell Biology, Chi-
ese Academy of Sciences, China. Fetal calf serum and high glucose
ulbecco’s modiﬁed Eagle’s medium (DMEM) were from Hyclone.
a2SO3, oleic acid, and tryptase were bought from Sigma. Pre-
tained protein marker was obtained from Fermentas, Western
lot substrate was from Thermo Scientiﬁc, human very low-density
ipoprotein (VLDL) (ESK5997) and human apolipoprotein B100
apoB100) (ESK5994) test kit were purchased from Shanghai San-
on Biological Engineering Technology & Services Co., Ltd., China.
G assay Kit (GPO-POD method) were bought from Applygen Tech-
ologies Inc., China.
The primary and secondary antibodies used in this study is listed
n Tables 1 and 2..2. Culture and treatment of cells
L-02 cells were cultured in high glucose DMEM containing 10%
alf serum in an incubator at 5% CO2 and 37 ◦C. The mediumrts 3 (2016) 98–104 99
was replaced every two-three days. Cells were digested and pas-
saged with 0.25% trypsin. After achieving 80% adhesion, they were
selected for the experiments. Seven treatment groups were set up
as the followings: one negative control group (complete medium),
four Na2SO3 treatment groups, and two  positive control groups
(1 mM oleic acid group and 10 mM carbon tetrachloride group). The
concentrations in the Na2SO3 treatment groups were conﬁgured as
10, 2.5, 0.5, and 0.1 mM according to previous report [15,37]. Cells
were routinely seeded onto a six-well culture plate, each group in
two wells. The extracellular supernatants after exposure for 24 and
48 h were collected for detecting VLDL and apoB100 contents in the
supernatant, and intracellular proteins were collected for protein
expression analysis. All the experiments were repeated thrice for
statistic analysis.
2.3. Detection of intra-hepatocellular TG level
Detection of TG in hepatocytes was performed as reference with
minor adjustment [38]. The cells were routinely seeded onto a 6-
well culture plate. After treatment the supernatants were removed
for further protein analysis. The cell pellets were washed with 2 ml
PBS. They were dispersed with 400 l of PBS/10 mM EDTA, pH
7.4. 200 l of cell suspension was  centrifuged and lysed for pro-
tein measurement. 200 l of cell suspension was added to glass
tubes with 2 ml  of isopropanol–hexane–water (IHW) for organic
extraction, vortexed and incubated with aluminum foil for 30 min.
Then 500 l of hexane–diethyl ether (1:1) was added to each tube.
Samples were vortexed, incubated and covered with aluminum
foil for 10 min  at room temperature. 1 ml  of water was added to
separate phases by vortexing. Another incubation covered with
aluminum foil until phases separate (∼20 min) at room temper-
ature. The organic phase (900 l) was  pipetted into a new glass
tube for nitrogen evaporation using a 96-well format manifold at
50 ◦C. Then 10 l water and 190 l of TG reagent were added to
each tube according to the instruction. The tubes were vortexed
and covered with paraﬁlm and incubated for 30 min  at 37 ◦C with
shaking at 100 rpm. Finally 150 l of TG reagent with samples was
dispensed to a ﬂat-bottom 96-well plastic microplate to determine
absorbance at 550 nm.
2.4. Determination of extra-hepatocellular TG content
The cells were routinely seeded onto a 24-well culture plate,
each treatment group in two  wells. The supernatants were col-
lected after exposure for 24 and 48 h, and the TG was  extracted
using organic extraction method similar to intracellular TG detec-
tion, evaporated by using a 96-pin microplate format gas manifold
[38]. 1 ml  of supernatant was used for extraction instead of 200 l
of cell suspension. The TG level was determined according to the
instructions provided along with the kit, and the experiment was
repeated 4 times.
2.5. Detection of secretions of VLDL and apoB100 of hepatocytes
treated with Na2SO3
VLDL and apoB100 in the supernatant was detected according
to the instructions provided with the kit.
2.6. Detection of protein expression
The intracellular proteins were collected using the loading
buffer after exposure for 24 and 48 h, and quantiﬁed by using
trichloroacetic acid method. A loading amount of 25–50 g protein
sample was collected for sodium dodecyl sulfate-polyacrylamide
gel electrophoresis using 10 or 15% separating gel and 5% spacer gel.
Separated proteins were transferred electronically to nitrocellulose
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Table 3
Effect of Na2SO3 treatment on the TG level of L-02 hepatocytes (n = 3, x¯ ± s).
Group TG (mmol  g−1)
24 h 48 h
Negative control 1.2218 ± 0.5272 1.4837 ± 0.1236
0.1 mM Na2SO3 1.2609 ± 0.4914 1.3167 ± 0.2209
0.5 mM Na2SO3 1.5099 ± 0.3047 1.9047 ± 0.5721
2.5 mM Na2SO3 1.8227 ± 0.4524 2.1050 ± 0.3275
10.0 mM Na2SO3 2.4713 ± 0.7691* 6.3060 ± 0.8734*
1.0 mM OA 3.0940 ± 0.7968* 3.0130 ± 0.6844*
10.0 mM CCl4 3.2353 ± 1.1168* 1.8090 ± 0.5705
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Fig. 1. Effect of Na2SO3 treatment on protein expression levels of CPT1 and SREBP1
in  L-02 hepatocytes. Cells were treated with Na2SO3 (as described in Section 2),
proteins were collected, equal total protein levels were loaded, and levels were
analyzed using western blot. The expression of CPT1 and SREBP1 was signiﬁcantly
reduced.
Table 4
Effect of Na2SO3 treatment on the secretion of TG from L-02 hepatocytes (n = 4, x¯ ± s).
Group TG(mmol/L)
24 h 48 h
Negative control 0.1203 ± 0.0354 0.5245 ± 0.0333
0.1 mM Na2SO3 0.5557 ± 0.1606* 0.6326 ± 0.1369*
0.5 mM Na2SO3 0.6477 ± 0.1084* 0.5881 ± 0.0633*
2.5 mM Na2SO3 0.5991 ± 0.1107* 0.6311 ± 0.0707*
10.0 mM Na2SO3 0.6399 ± 0.0759* 0.7501 ± 0.0990*
1.0 mM OA 0.4586 ± 0.0453* 1.0816 ± 0.0111*
10.0 mM CCl 0.7163 ± 0.0879* 0.7027 ± 0.0948*ells were treated with Na2SO3 (as described in Section 2), the lipids in the cells
ere extracted with hexane-isopropanol-diethyl ether, and quantiﬁed.
* P < 0.05 when compared to negative control.
embrane. Membrane was blocked with 5% defatted milk powder
t room temperature for 1 h. Blocked membranes were incubated
ith corresponding ﬁrst antibody (CPT1a 1:1000, SREBP1c 1:1000,
TP 1:1000, TGH 1:3000, Arf1 1:2000, COP  1:1000, LDLR 1:1000,
-actin 1:1000) in a 4 ◦C shaker overnight. Later the membranes
ere shaken and rinsed thrice with phosphate-buffered saline with
ween 20 (PBST) at room temperature. Secondary antibody cou-
led with horse radish peroxidase (goat anti-rabbit 1:4000 and goat
nti-mouse 1:4000) was added and incubated at room temperature
or 1 h. The protein expression was detected using enhanced chemi-
uminescence. -actin was detected for loading control of same
mount of total protein. Films were developed, the optical den-
ity in hybridization maps was semiquantitatively analyzed using
mage-Pro Plus 6.0 software.
.7. Statistical analysis
Statistical analyses were performed using SPSS17.0 software,
nd the results were expressed as mean ± standard error. One-
actor analysis of variance was used to compare the mean values
f various groups. Multiple comparisons between groups were
erformed using Dunnett’s t test. A difference with P < 0.05 was
onsidered statistically signiﬁcant.
. Results
.1. Na2SO3 has no signiﬁcant effects on intra-hepatocellular TG
evel of human L-02
Na2SO3 could increase lipid droplets in mouse [22], herein we
xamined its effects on the TG level in human hepatocytes. The
resent results showed that TG level in hepatocytes treated by
.1 mM–2.5 mM Na2SO3 was not signiﬁcantly increased, but the TG
evel in hepatocytes was increased signiﬁcantly by 10 mM Na2SO3
4 h/48 h exposure, accompanied by cell death (Table 3).
.2. Na2SO3 increases extra-hepatocellular TG level of human
-02
TG content in extra-hepatocytes was detected by GPO-POD
ethod. The present results showed that TG level in the super-
atant of hepatocytes was signiﬁcantly increased when treated
y 0.1mM–10 mM Na2SO3, (*P < 0.05). As control settings, OA or
Cl4 treatment also increased the TG content in the supernatant
Table 4). It means that Na2SO3 can increase the secretion of TG
rom hepatocytes..3. Na2SO3 promotes secretion of VLDL in L-02 hepatocytes
As illustrated in Table 5, after 24 h exposure to Na2SO3, VLDL
ontent in the supernatant of each Na2SO3 group was signiﬁcantly
4
Cells were treated with Na2SO3 (as described in Section 2), the lipids in the super-
natants were extracted with hexane-isopropanol-diethyl ether, and quantiﬁed.
* P < 0.05 when compared to negative control.
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Fig. 2. Effect of Na2SO3 treatment on protein expression levels of VLDL assembly-related proteins (MTP and TGH) and transportation-related proteins (Arf1 and COP ) in
L eins w
r  TGH i
e
i
r
a
c
c
3
h
t-02  hepatocytes. Cells were treated with Na2SO3 (as described in Section 2), prot
eference, and levels were analyzed using western blot. The expressions of MTP  and
xposure. Arf1 and COP  were increased after 48 h exposure.
ncreased as compared with the negative control (P < 0.05). This
esult suggests that Na2SO3 promotes the secretion of VLDL in hep-
tocytes. However, after exposure to Na2SO3 for 48 h, the VLDL
ontent in each treatment group did not signiﬁcantly change as
ompared with the negative control.
.4. Na2SO3 promotes the secretion of apoB100 in L-02
epatocytes
After exposure to Na2SO3 for 24 or 48 h, the apoB100 con-
ents in the supernatant of extracellular medium were signiﬁcantlyere collected, equal total protein levels were loaded by detection of -actin as a
n each Na2SO3 group and positive control were signiﬁcantly increased after 24/48 h
increased as compared with the negative control group (P < 0.05).
This reﬂected that in a dose dependent manner, Na2SO3 can pro-
mote the secretion of apoB100 in hepatocytes.
3.5. Na2SO3 suppresses the expressions of CPT1 and SREBP1
CPT1 is a key rate-limiting enzyme for fatty acid decomposition
in hepatocytes, and SREBP1 is an important transcription factor that
promotes the expression of fat synthesis related genes. After expo-
sure to Na2SO3 for 24 h and 48 h, the expressions of CPT1 protein in
0.1–10 mM Na2SO3 treatment groups were signiﬁcantly reduced.
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Table 5
Effect of Na2SO3 treatment on the secretion of VLDL from L-02 hepatocytes (n = 3,
x¯  ± s).
Group VLDL(mol/L)
24 h 48 h
Negative control 242.08 ± 3.52 239.00 ± 7.05
0.1 mM Na2SO3 278.23 ± 6.01** 287.97 ± 14.21
0.5 mM Na2SO3 296.44 ± 2.47* 289.77 ± 29.08
2.5 mM Na2SO3 276.44 ± 33.09* 256.44 ± 25.48
10.0 mM Na2SO3 263.10 ± 10.24* 235.92 ± 32.31
1.0 mM OA 300.54 ± 12.66* 271.82 ± 36.20
10.0 mM CCl4 245.40 ± 15.46 237.46 ± 20.16
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Fig. 3. Effect of Na2SO3 treatment on protein expression level of LDLR.
Cells were treated with Na2SO3 (as described in Section 2), proteins were collected,ells were treated with Na2SO3 (as described in Section 2), the supernatants were
ollected and VLDL contents were quantiﬁed.
* P < 0.05 when compared to negative control.
his suggests that Na2SO3 exposure can suppress -oxidation of
epatic fatty acids, which is conducive to the synthesis of TG. After
xposure for 24 h, the expression of SREBP1 was decreased by
a2SO3; while after 48 h exposure, the expressions of SREBP1 were
igniﬁcantly decreased in the 2.5–10 mM Na2SO3 groups. This simi-
ar responsiveness as OA treatment indicates that hepatocytes may
ounteract the risk of increased synthesis of TG.
.6. Na2SO3 promotes the expression of TG transfer protein in
-02 hepatocytes
MTP  is responsible for the assembly of TG and apoB100 to
enerate primary VLDL. TGH is responsible for hydrolysis and re-
steriﬁcation of TG in endochylema of hepatocytes, followed by
ssembly with apoB100 to generate VLDL. At least 70% of the TG in
he hepatocytes enters VLDL through this route. The initial prod-
cts of VLDL are transported into the Golgi apparatus with the
ffects of Arf1 and COP I after their generation in the endoplas-
ic  reticulum, followed by further processing for secretion. After
xposure to Na2SO3 for 24 and 48 h, the expressions of MTP  and
GH in each Na2SO3 group and positive control were signiﬁcantly
ncreased (Fig. 2a). The expressions of Arf1 and COP  protein were
ncreased signiﬁcantly after exposure to Na2SO3 for 48 h (Fig. 2b).
he above results indicated that Na2SO3 may  promote the expres-
ions of MTP  and TGH proteins, and in the same time upregulate
rf1 and COP  proteins for more VLDL secretion.
.7. Na2SO3 inhibits the expression of LDLR protein in L-02
epatocytes
The LDLR in the liver is primarily responsible for removal of
DL from the circulation. It has been speculated that LDLR affects
lasma apoB containing lipoprotein (Blp) metabolism by uptake
DL from the plasma by apoB100 and apoE related pathway. It is
lso responsible for the uptake of VLDL in vitro. Similar to positive
ontrol (OA and CCl4 groups), Na2SO3 experimental groups have
igniﬁcant lower LDLR expression than the negative control (Fig. 3).
hat means that Na2SO3 may  inhibit the uptake of VLDL/LDL from
he supernatant of L-02.
. Discussion
Na2SO3 is a common reductive food additive, but it is also a
etabolic derivative of the air pollutant sulfur dioxide in the body.
revious animal experiments have found that inhalation of sul-
ur dioxide could increase hepatic lipid droplets and TG level and
ncrease the plasmic TG content in mouse liver [22,23]. We  hypoth-
sized that exposure to Na2SO3 may  cause metabolic disorder of
uman liver, thereby lead to NAFLD by inhibition the secretion of
LDL. At present, NAFLD is a burgeoning health problem affectingequal total protein levels were loaded by detection of -actin as a reference, and
levels were analyzed using western blot. LDLR expression was inhibited by Na2SO3
treatment for 24/48 h (similar as OA and CCl4).
one-third of adults and an increasing number of children in devel-
oped countries. The NAFLD begins with the aberrant accumulation
of triglyceride in the liver. Some individuals elicits an inﬂammatory
response that can progress to cirrhosis or liver cancer [24–27].
In this study, both intra- and extra-hepatocellular TG contents
from L-02 were examined after exposure to Na2SO3. The results
showed that Na2SO3 has no direct effect on TG content in the human
liver cells. At a higher concentration (10 mM),  Na2SO3 signiﬁcantly
increased the TG content and cell death (75% for 24 h, 50% for 48 h,
data not shown) (Table 3). But, Na2SO3 promotes the secretion
and exocytosis of TG (Table 4). Our data suggest that Na2SO3 may
not induce NAFLD directly. We  also did not ﬁnd the inhibition of
VLDL secretion, on the contrary, the ﬁndings of the present study
revealed that Na2SO3 was  able to promote the secretions of VLDL
and apoB100 (Tables 5 and 6).
It was reported that the fat content in the hepatocytes is con-
trolled by the decomposition of the fatty acid and synthetic rate
of TG [29]. CPT1 is the key rate-limiting enzyme for the decom-
position of fatty acid in hepatocytes. Suppression of CPT1 activity
might lead to increased TG synthesis, thereby cause TG accumu-
lation [31,39]. Our data showed that the expression of CPT1 was
signiﬁcantly inhibited by Na2SO3 exposure (Fig. 1), suggesting that
Na2SO3 has the potential to increase the TG content in the hep-
atocytes. Interestingly, we  did not ﬁnd signiﬁcant increase of TG
in cells. Probably the inhibition of CPT1 is not strong enough or
other counteract factors are involved in the TG processing. In this
study, the expression of SREBP1c was markedly reduced after expo-
sure to Na2SO3 similar to 1 mM OA treatment (Fig. 1) [40]. SREBP1c
mainly regulates the synthesis of fatty acids by enhancing tran-
scription of the genes encoding acetyl CoA carboxylase, fatty acid
synthase, stearoyl CoA desaturase-1 [41,42]. Our results indicated
that Na2SO3 may  increase the synthesis of TG through the inhibition
of CPT1. But hepatocytes can mobilize their protective mechanism
to response to this possible adverse effect under mild threat. How-
ever, since in vitro experiments can only reﬂect the short-term
J. Bai et al. / Toxicology Repo
Table  6
Effect of Na2SO3 treatment on the secretion of apoB100 from L-02 hepatocytes (n = 3,
x¯  ± s).
Group apoB100(ng/ml)
24 h 48 h
Negative control 135.13 ± 3.33 143.59 ± 13.44
0.1 mM Na2SO3 155.90 ± 6.63* 171.03 ± 3.62*
0.5 mM Na2SO3 177.95 ± 8.75* 197.69 ± 2.47*
2.5 mM Na2SO3 199.49 ± 2.35* 240.26 ± 3.33*
10.0 mM Na2SO3 235.64 ± 3.95* 255.13 ± 2.96*
1.0 mM OA 201.54 ± 5.81* 230.00 ± 5.40*
10.0 mM CCl4 231.79 ± 5.46* 263.33 ± 4.62*
Cells were treated with Na2SO3 (as described in Section 2), the supernatants were
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[ollected, and apoB100 contents were quantiﬁed.
* P < 0.05 when compared to negative control.
ffect of a toxicant on the body or cells, further in-depth studies
re required to investigate long-term effect Na2SO3 exposure.
In addition to fatty acid decomposition and fat synthesis, VLDL
ecretion is a key factor that affects the TG level in the hepato-
ytes [43,28,29]. This study investigated the assembly and secretion
f VLDL of L-02 hepatocytes after exposure to Na2SO3. After 24 h
xposure, the VLDL content in the supernatant was  signiﬁcantly
ncreased (Table 5). This result is consistent with our previous
esults using protein hybridization (data not shown), and further
roved that Na2SO3 is prone to promote the secretion of VLDL.
eanwhile, it was also found that exposure to Na2SO3 could pro-
ote the secretion of apoB100 (Table 6).
In normal physiological condition, TG should be effectively and
roperly assembled and transported before VLDL secretion. This
omplex process requires many important protein molecules. Our
tudy mainly focused on four types of commonly recognized pro-
eins, that is MTP, TGH, Arf1 and COPI. Initially, MTP  was discovered
o catalyze the transportation of neutral lipids, and serves as an
ssential molecule for the assembly and maturation of lipoprotein
LDL, which contains abundant apoB100 [29,44,45]. Studies have
ound that inhibition of MTP  activity by chemical inhibitor might
ead to failure of VLDL assembly [46], while the secretion of VLDL
ight be elevated with increased expression of MTP  [31]. In this
tudy, the expressions of MTP  in the hepatocytes were signiﬁcantly
ncreased after exposure to Na2SO3 (Fig. 2), thereby we speculate
hat MTP  is associated with increased secretions of VLDL (Table 5)
nd apoB100(Table 6) in the hepatocytes. TGH is involved in the
ydrolysis and re-esteriﬁcation of TG in the VLDL assembly [34].
ore than 70% of the TG in the hepatocytes can be evacuated after
ydrolysis and re-esteriﬁcation. An elevated TGH expression in the
epatocytes may  enhance its mobilization and the re-esteriﬁcation
47,48]. On the contrary, inhibition of TGH activity in the hepato-
ytes may  lead to limited mobilization of TG and reduced secretion
f VLDL [33]. Our study found that the expression of TGH was sig-
iﬁcantly increased after exposure to Na2SO3 suggesting that TGH
lternation is associated with the increased Na2SO3-related secre-
ions of VLDL and apoB100. The effects of Na2SO3 on the expressions
f Arf1 and COP  proteins were also studied. Arf1 is an important
olecule for sorting and transporting proteins from the endoplas-
ic  reticulum to the Golgi apparatus. Arf1 can also facilitate the
unctions of mitochondria and endoplasmic reticulum [49,50]. Arf1
s necessary for the movement of special secretory vesicles VLDL
recursor from the endoplasmic reticulum to cis-face of the Golgi
pparatus, where an overexpression of Arf1 might promote the
ecretion of VLDL [35]. COP  is one of COPI’ s subunits. This exper-
ment showed that Na2SO3 promotes the expression of Arf1 and
OP, suggesting that they are associated with the promoting effect
f Na2SO3 on secretions of apoB100.
We  observed increased VLDL content in the supernatant
fter Na2SO3 exposure. LDLR is transcriptionally regulated by
[rts 3 (2016) 98–104 103
the sterol regulatory element binding protein 2 (SREBP-2). LDLR
is also post-translationally regulated by proprotein convertase
subtilisin/kexin-type 9 (PCSK9) and inducible degrader of the LDLR
(IDOL) [51–55]. We  found that Na2SO3 decreased the expression of
LDLR, it means that it can inhibit the uptake of VLDL in the super-
natant. It may  also contribute to the increase of VLDL and apoB100
in the supernatant.
In summary, this study indicated that exposure to Na2SO3 has
little effects on the fat accumulation in human hepatocytes. How-
ever, Na2SO3 may  promote the secretions of VLDL and apoB100,
and increase the expressions of MTP  and TGH. As these proteins
are related to VLDL assembly, our results indicate that Na2SO3 may
promote the secretions of VLDL and apoB100 through MTP  and
TGH pathway. This study also suggests that exposure of Na2SO3
may  decrease the expression to LDLR which may contribute to the
increase of VLDL secretion.
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